首页|丹参酮ⅡA对胆道闭锁肝纤维化大鼠SMAD4 SMAD7及Ⅰ型胶原蛋白的影响

丹参酮ⅡA对胆道闭锁肝纤维化大鼠SMAD4 SMAD7及Ⅰ型胶原蛋白的影响

扫码查看
目的 探讨丹参酮ⅡA通过调控SMAD4、SMAD7蛋白延缓胆道闭锁肝纤维化的机制.方法 30只雄性SD大鼠按照随机数字表法分为正常组、假手术组、模型组、吡非尼酮组(300 mg/kg)和丹参酮ⅡA组(20 mg/kg),每组6只.除正常组和假手术组外,其余各组鼠采用胆总管注射无水乙醇的方法复制胆道闭锁肝纤维化模型,造模后第1天,吡非尼酮组和丹参酮ⅡA组鼠给予相应药物灌胃,假手术组和模型组鼠给予等体积生理盐水(10 mL/kg)灌胃.给药20 d 后,采用戊巴比妥钠过量麻醉动物留取标本,比较各组间大鼠血液生化指标及肝脏组织病理学改变;检测血清谷丙转氨酶、谷草转氨酶、总胆红素水平;Western blot检测肝组织SMAD4、SMAD7的表达以及肝组织中collagen Ⅰ的表达.结果 与正常组相比,模型组大鼠血清谷丙转氨酶、谷草转氨酶、总胆红素升高(P<0.05),肝组织呈明显的纤维化改变,肝组织SMAD4、collagen Ⅰ蛋白表达水平升高,SMAD7表达降低(P<0.05);丹参酮ⅡA治疗后,SMAD4、collagen Ⅰ表达水平下降,SMAD7表达升高(P<0.05),且大鼠肝纤维化较吡非尼酮组明显减轻.结论 丹参酮ⅡA可以有效延缓胆道闭锁肝纤维化进展,其机制可能通过调节TGF-β/Smads中关键蛋白SMAD4及SMAD7的表达,从而减少肝组织中collagen I的沉积.
Mechanism of ligustrazine retards hepatic fibrosis via TGF-β/Smad channelin biliary atresia
Objective To investigate the mechanism of tanshinone ⅡA delaying hepatic fibrosis in biliary atresia by regulating SMAD4 and SMAD7 proteins.Methods Thirty male SD rats were divided into the normal group,sham operation group,model group,pirfeni-done group(300 mg/kg)and tanshinone ⅡA group(20 mg/kg)according to random number table,with six rats in each group.In addition to the normal group and sham operation group,the other groups of rats were injected with anhydrous ethanol in the common bile duct to replicate the biliary atresia liver fibrosis model.On the first day after modeling,the rats in the pirfenidone group and tanshinone ⅡA group were given corre-sponding drugs,and the rats in the sham operation group and model group were given equal volume normal saline(10 mL/kg).After 20 days of administration,specimens were taken from animals overanesthetized with pentobarbital sodium,biochemical indexes and histopathological changes of liver were compared.Serum alanine aminotransferase,aspartate aminotransferase and total bilirubin levels were detected.Western blot analysis was performed to detect the expression of SMAD4 and SMAD7 and collagen Ⅰ in liver tissue.Results Compared with normal group,serum alanine aminotransferase,aspartate aminotransferase and total bilirubin in model group were increased(P<0.05),liver tissue showed obvious fibrosis changes,collagen Ⅰ and SMAD4 expression were increased,and SMAD7 expression was decreased(P<0.05).However,the expressions of SMAD4 and collagen Ⅰ in the pirfenidone group and tanshinone ⅡA group decreased,while the expression of SMAD7 in-creased(P<0.05),and tanshinone ⅡA group had obvious advantages in improving liver fibrosis compared with pirfenidone group.Conclu-sions Tanshinone ⅡA can effectively delay the progression of liver fibrosis in biliary atresia,possibly by regulating the expression of key pro-teins SMAD4 and SMAD7 in TGF-β/Smads,thereby reducing the deposition of collagen Ⅰ in liver tissue.

TanshinoneⅡ ABiliary atresiaLiver fibrosisTGF-β1/Smads pathway

宋海容、邱建利、李灿灿、华春兰、段昱

展开 >

450000 河南郑州 郑州大学第一附属医院检验科

450000 河南郑州 河南中医药大学第一附属医院儿科

丹参酮ⅡA 胆道闭锁 肝纤维化 TGF-β1/Smads通路

国家自然科学基金

81804142

2024

安徽医学
安徽省医学情报研究所

安徽医学

CSTPCD
影响因子:1.123
ISSN:1000-0399
年,卷(期):2024.45(5)